Myrexis Articles
Myrexis board approves liquidation and dissolution plan
12 November 2012
Myrexis returns rights to Azixa to EpiCept
6 September 2012
Myrexis to drop development of Azixa; 4th-qtr loss widens; names new CEO
13 September 2011
Myriad Pharma to focus on oncology portfolio, cutting staff to conserve financial resources
9 June 2010
Showing 1-4 of 4 articles
- 1
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
